Salix's Pharmaceuticals (SLXP) Once-Daily APRISO Demonstrates Long-Term Safety in Patients for Maintenance of Remission From Ulcerative Colitis
Tweet Send to a Friend
Data was announced today that demonstrated Salix Pharmaceuticals' (NASDAQ: SLXP) APRISO (mesalamine) 0.375g extended-release capsules had a favorable safety profile ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
